Can treatment be interrupted after taking dacomitinib/dacomitinib?

Dacomitinib/Dacomitinib (Dacomitinib) is an irreversible EGFR tyrosine kinase inhibitor, mainly used to treat patients with epidermal growth factor receptor mutation non-small cell lung cancer (NSCLC). As an oral targeted drug, it blocks the proliferation and spread of cancer cells by inhibiting the EGFR signaling pathway. Because of the specific mechanism of action and therapeutic window of this drug, you must be very careful about whether you can interrupt the treatment during use, and you cannot stop the drug at will.

In clinical practice, whether to interrupt dacomitinib treatment usually depends on two key factors: the patient's tolerance to the drug and changes in the condition. If a patient experiences significant adverse reactions while taking the drug, such as severe rash, diarrhea, abnormal liver function, or rapid weight loss, the doctor may recommend a short-term discontinuation of the drug to alleviate the side effects and readjust the dose to continue treatment after the patient recovers. This brief drug withdrawal is part of a "drug holiday" management strategy designed to improve patient compliance and quality of life. However, not all side effects require discontinuation of medication, and some minor discomforts can be alleviated through symptomatic treatment, dietary modification, or topical medications without completely interrupting treatment.

In addition, in terms of efficacy evaluation, if the patient's tumor is stable or significantly reduced and continues to benefit, it is generally recommended to continue taking dacomitinib until the disease progresses or uncontrollable side effects occur. Premature discontinuation of treatment may lead to tumor recurrence or even accelerated progression. Especially hasty discontinuation of treatment before optimal efficacy has been achieved, which may adversely affect the overall treatment effect. Therefore, patients should not stop taking medication without authorization due to personal subjective judgment or fear of side effects, and should always adjust the treatment rhythm according to professional medical advice.

It needs to be emphasized that once treatment needs to be interrupted, the patient should discuss it in detail with the attending physician, assess the risks and benefits, and make arrangements for review and follow-up treatment.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro